BioNTech and Pfizer (PFE) confirm preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2  (66.74) $BNTX $PFE $MRNA $GILD $SRNE